European vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms

Table 12 2015 update on the molecular landscape findings in the chronic phase of essential thrombocythemia, polycythemia vera and myelofibrosis and during blast phase of myeloproliferative neoplasms transformation[121]

Gene	Chronic phase ET, PV and MF	Blast phase/AML
JAK2V617F	PV: 95%-98%; ET and MF: 50%-60%
MPL	ET: 1.5%; MF: 5%-10%
TET2	PV: 7%-16%; ET: 4%-11%; MF: 8%-17%
ASXL	PV: 2%; ET: 5%-8%; MF: 7%-17%	19%
DNMT3A	PV: 7%; ET: 3%; MF: 7%-15%	17%
CBL	MF: 6%
LNK	PV, ET, MF: < 5%	10%
IDH 1/2	MF: 4%	21%
IKZF		19%
EZH2	MPNs: 5%-13%
P53		27%
SRSF2		19%

MF: Myelofibrosis; PV: Polycythemia vera; ET: Essential thrombocythemia; AML: Acute myeloid leukemia.